Comparison of noninvasive models of fibrosis in chronic hepatitis B

Hepatology International

Volumn 6, Issue 2, 2012, Pages 457-467

  Raftopoulos, S C ^a   George, J ^b   Bourliere, M ^c   Rossi, E ^d   De Boer, W B ^d   Jeffrey, G P ^a,e   Bulsara, M ^f   Speers, D J ^d   MacQuillan, G ^a,e   Ching, H L I ^e   Kontorinis, N ^g   Cheng, W ^g   Flexman, J ^d   Fermoyle, S ^d   Rigby, P ^h   Walsh, L ^h   McLeod, D ^b   Adams, L A ^a,e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HÔPITAL SAINT JOSEPH   (France)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF NOTRE DAME   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

APRI; Fibrosure; Fibrotest; Hepascore; Image morphometry

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN;

ACCURACY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APRI MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROTEST MODEL; HEPASCORE MODEL; HEPATITIS B; HEPATITIS B(E) ANTIGEN POSITIVE AND NEGATIVE MODEL; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MODEL; MORPHOMETRICS; NONINVASIVE FIBROSIS MODEL; PATIENT IDENTIFICATION; PATIENT MONITORING; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERUM FIBROSIS MODEL;

EID: 84862853889     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9296-5     Document Type: Article

References (23)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-1745
2. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development conference statement: management of hepatitis B. Ann Intern Med 2009;150:104-110
3. Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008;25:1-29
4. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-1400
5. Van Thiel DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy. Its safety and complications as seen at a liver transplant center. Transplantation 1993;55:1087-1090
6. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56
7. Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134: 1376-1384
8. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-767
9. Zeng M, Lu LG, Mao Y, et al. Prediction of significant fibrosis in HBeAg-positive patients with chroic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-1445
10. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006;101: 2345-2537
11. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-1873
12. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic Hepatitis C. Gastroenterology 2005;128:343-350
13. Chun-Tao W, Joel KG, Robert JF, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526
14. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009;50:1738-1749
15. Hu KQ, Schiff ER, Kowdley KV, et al. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010;44:510-516
16. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-454
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative study group. Hepatology 1996;24:289-293
18. Bottero J, Lacombe K, Guechot J, et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol 2009;50:1074-1083
19. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-230
20. Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol 2007;46:543-545
21. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662
22. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751